Austin, TX Clinical Trials Report — May 2026

For Austin residents interested in contributing to medical research, May 2026 presents both immediate opportunities and exciting new avenues for participation. A total of 34 clinical trials in Austin are slated to conclude enrollment within the next 90 days, making prompt action essential for interested individuals.

Among these rapidly closing studies, 4 are still actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close. These trials provide a valuable opportunity for individuals without specific health conditions to support the development of new treatments.

Urgent Opportunities in Key Health Areas

Patients managing specific health conditions also have limited time to join research. Trials focused on various cancers and heart conditions are among those with impending deadlines for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (3 trials)
• Cancer (3 trials)
• Metastatic cancer (3 trials)
• Non-small cell lung cancer (3 trials)
• Cutaneous melanoma (2 trials)
• Heart failure (2 trials)
• Acute myeloid leukemia (1 trial)
• Acute lymphoblastic leukemia (1 trial)
• Acute gouty arthritis (1 trial)
• Amyotrophic lateral sclerosis (1 trial)

New Research Opportunities Emerge in Austin

This month, Austin saw the opening of 16 new clinical trials, an increase from the 10 trials that launched in April 2026. This brings the total number of actively recruiting clinical trials in Austin, TX, to 644 across 391 research facilities, highlighting the city's active research landscape.

May brings several high-profile new trials to Austin, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial plans for 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss.
• AbbVie is sponsoring a Phase 2/3 study, NCT07592273, "Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema." This study involves 576 participants and will assess a new treatment for Diabetic Retinopathy, a common eye condition caused by diabetes.
• Eli Lilly and Company is leading a Phase 3 study, NCT07602582, "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This trial, with 550 participants, aims to determine if participants who previously took donanemab for Alzheimer's disease receive clinical benefit from annual doses.
• Also from Eli Lilly and Company, a Phase 2 study, NCT07589608, "A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight." This trial aims for 400 participants to examine the body weight-lowering efficacy and safety of new compounds for obesity or overweight individuals without type 2 diabetes.

New trials this month are exploring a range of conditions, with the most frequent being obesity (4 trials), overweight (2 trials), and locally advanced (unresectable) or metastatic solid tumors (2 trials). Drug trials were the most common type among new studies, with 15, followed by 2 other types of studies, 1 device trial, and 1 radiation trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 3 of the 16 new trials launched this month are actively seeking healthy volunteers. Across Austin, a total of 56 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Austin's Leading Research Facilities

Austin is home to several active research sites that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Dell Children's Medical Center of Central Texas (35 trials)
• Research Site (24 trials)
• The University of Texas at Austin (20 trials)
• University of Texas at Austin (20 trials)
• Texas Cardiac Arrhythmia Research Foundation (12 trials)
• Dell Children's Medical Center (10 trials)
• Austin Heart (10 trials)
• NEXT Austin (9 trials)
• GSK Investigational Site (9 trials)
• Austin Retina Associates (8 trials)
• Texas Oncology - Central South (8 trials)
• FutureSearch Trials of Neurology (8 trials)

These institutions offer a broad spectrum of research, from pediatric care at Dell Children's Medical Center to cardiac studies at Texas Cardiac Arrhythmia Research Foundation and Austin Heart, and oncology research at Texas Oncology.

Broadening Your Search: Nearby Options

While Austin offers a significant array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include Houston (45 trials), Dallas (31 trials), San Antonio (20 trials), McAllen (4 trials), El Paso (4 trials), Fort Worth (4 trials), Plano (3 trials), and Bellaire (3 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 16 new trials launched this month, 15 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials this month are specifically for children, female-only, or male-only participants. Industry sponsors continue to drive significant research efforts in Austin, with 16 new industry-sponsored trials this month, including those from Novo Nordisk A/S (3 trials), NEOK Bio, Inc. (2 trials), and Eli Lilly and Company (2 trials).

As we move through May, Austin's growing research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.